SSRP1 Rabbit Polyclonal Antibody
CAT#: TA308461
Rabbit polyclonal antibody to SSRP1 (structure specific recognition protein 1)
Need it in bulk or conjugated?
Get a free quote
CNY 6281.00
| Cited in 1 publication. |
CNY 3080.00
CNY 300.00
CNY 1430.00
CNY 2900.00
CNY 6650.00
CNY 9998.00
Specifications
| Product Data | |
| Applications | IHC, WB |
| Recommend Dilution | IHC:1:100-1:1000; WB:1:500-1:3000 |
| Reactivity | Human, Rat, Bovine, Rhesus Monkey, Mouse |
| Host | Rabbit |
| Clonality | Polyclonal |
| Immunogen | Recombinant fragment corresponding to a region within amino acids 75 and 338 of SSRP1 (Uniprot ID#Q08945) |
| Isotype | IgG |
| Formulation | 0.1M Tris, 0.1M Glycine, 10% Glycerol (pH7). 0.01% Thimerosal was added as a preservative. |
| Purification | Purified by antigen-affinity chromatography. |
| Conjugation | Unconjugated |
| Storage Condition | Store at -20°C as received. |
| Predicted Protein Size | 81 kDa |
| Gene Name | structure specific recognition protein 1 |
| Database Link | |
| Background | The protein encoded by this gene is a subunit of a heterodimer that, along with SUPT16H, forms chromatin transcriptional elongation factor FACT. FACT interacts specifically with histones H2A/H2B to effect nucleosome disassembly and transcription elongation. FACT and cisplatin-damaged DNA may be crucial to the anticancer mechanism of cisplatin. This encoded protein contains a high mobility group box which most likely constitutes the structure recognition element for cisplatin-modified DNA. This protein also functions as a co-activator of the transcriptional activator p63. An alternatively spliced transcript variant of this gene has been described, but its full-length nature is not known. [provided by RefSeq] |
| Synonyms | FACT; FACT80; T160 |
| Note | Seq homology of immunogen across species: Mouse (100%), Rat (100%), Rhesus Monkey (100%), Bovine (100%) |
| Reference Data | |
| Protein Families | Transcription Factors |
Citations (1)
| The use of this Antibodies has been cited in the following citations: |
|---|
|
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG
,Ehteda, A;Simon, S;Franshaw, L;Giorgi, FM;Liu, J;Joshi, S;Rouaen, JRC;Pang, CNI;Pandher, R;Mayoh, C;Tang, Y;Khan, A;Ung, C;Tolhurst, O;Kankean, A;Hayden, E;Lehmann, R;Shen, S;Gopalakrishnan, A;Trebilcock, P;Gurova, K;Gudkov, AV;Norris, MD;Haber, M;Vittorio, O;Tsoli, M;Ziegler, DS;,
Cell reports
,PubMed ID 33852836
[SSRP1]
|
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
| 抗体相关资料 |
